Treating Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in the Czech Republic: Cost-Effectiveness of IDegLira Versus iGlarLixi
Open Access
- 31 January 2019
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 10 (2) , 493-508
Abstract
Introduction Few patients with type 2 diabetes mellitus (T2DM) achieve recommended glycemic control targets in the Czech Republic. Novel therapies, such as fixed-ratio combinations of basal insulin plus glucagon-like peptide-1 receptor agonists, may contribute to better glycemic control. In the analysis presented here, the present analysis assessed the long-term cost-effectiveness of two fixed-ratio combinations, IDegLira (insulin degludec/liraglutide) and iGlarLixi (insulin glargine/lixisenatide), for the treatment of patients with T2DM inadequately controlled with basal insulin from a healthcare payer perspective in the Czech Republic. Methods A cost-effectiveness analysis was performed over patient lifetimes using the IQVIA CORE Diabetes Model. Treatment effects were obtained from an indirect treatment comparison as no head-to-head data for IDegLira versus iGlarLixi are currently available. IDegLira was compared with two iGlarLixi pens (100 U/mL insulin glargine + 33 μg/mL and 50 μg/mL of lixisenatide, respectively). Direct medical costs associated with pharmaceutical interventions, screening and diabetes-related complications were captured. Deterministic and probabilistic sensitivity analyses were performed. Results IDegLira was associated with gains in life expectancy of 0.11 years and in quality-adjusted life expectancy of 0.14 quality-adjusted life-years (QALYs) versus iGlarLixi, due to a lower cumulative incidence and delayed onset of diabetes-related complications. IDegLira was also associated with higher projected costs due to higher acquisition costs; however, these were partially offset by cost savings from avoided complications. IDegLira was associated with incremental cost-effectiveness ratios of Czech Koruna (CZK) 695,998 and CZK 348,323 per QALY gained versus iGlarLixi pens containing 33 and 50 μg/mL of lixisenatide, respectively. These ratios were below the commonly used willingness-to-pay threshold of CZK 1,200,000 per QALY gained. Conclusion The present analysis indicated that IDegLira was associated with clinical benefits relative to iGlarLixi over patient lifetimes and was likely to be cost-effective in the treatment of patients with T2DM uncontrolled on basal insulin in the Czech Republic. Funding Novo Nordisk. Plain Language Summary Plain language summary is available for this article.Keywords
Funding Information
- Novo Nordisk
This publication has 46 references indexed in Scilit:
- Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countriesHealth and Quality of Life Outcomes, 2013
- Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetesCurrent Medical Research and Opinion, 2006
- Evaluation of the association between the EQ‐5Dindex (health‐related utility) and body mass index (obesity) in hospital‐treated people with Type 1 diabetes, Type 2 diabetes and with no diagnosed diabetesDiabetic Medicine, 2005
- Modelling EuroQol health‐related utility values for diabetic complications from CODE‐2 dataHealth Economics, 2004
- Guidelines for Computer Modeling of Diabetes and Its ComplicationsDiabetes Care, 2004
- Quality of life on chronic dialysis: comparison between haemodialysis and peritoneal dialysisNephrology Dialysis Transplantation, 2004
- The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-makingCurrent Medical Research and Opinion, 2004
- Validation of the CORE Diabetes Model Against Epidemiological and Clinical StudiesCurrent Medical Research and Opinion, 2004
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)The Lancet, 1998
- Foundations of Cost-Effectiveness Analysis for Health and Medical PracticesNew England Journal of Medicine, 1977